Here's what we'll cover
Here's what we'll cover
The pharmacist says "We're out of Wegovy, try back next week." You call three more pharmacies. All out. You check online. "Temporarily unavailable." Your insurance-approved prescription sits unfilled while you scramble to find supply.
This was the reality for millions of GLP-1 users from 2022 through early 2025. Demand surged dramatically between 2021 and 2023, driven by expanded prescribing for weight loss., overwhelming Novo Nordisk and Eli Lilly's production capacity. Patients with type 2 diabetes couldn't access their prescribed medications. Weight loss patients faced months-long waitlists. Prices spiked. Black markets emerged.
The good news: The worst is over. FDA officially declared the semaglutide and tirzepatide shortages resolved in 2025. Supply now meets demand nationally. But "resolved" doesn't mean the medication magically appears at every pharmacy immediately. Localized supply disruptions still happen. Understanding where to find medication, which alternatives exist, and how to prevent future supply gaps helps you maintain treatment continuity.
This guide covers the current shortage status for every GLP-1 medication, where to find supply when your pharmacy is out, what happened to compounded alternatives, and strategies for ensuring you never run out in 2026.
Current Shortage Status by Medication (February 2026)
GLP-1 Availability Status February 2026
Semaglutide (Wegovy/Ozempic): SHORTAGE RESOLVED
Timeline:
- March 2022: Shortage begins due to demand surge
- 2022-2024: Intermittent availability, widespread stock-outs
- February 2025: FDA declares shortage resolved
- February 2026: Supply stable, all doses available
What Changed:
Novo Nordisk increased manufacturing capacity at facilities in Denmark, France, and North Carolina. Company now produces enough to meet current demand (estimated 15-20 million prescriptions annually) plus projected growth.
Current Reality:
Most pharmacies stock Wegovy and Ozempic regularly. Occasional stock-outs still occur at individual locations due to distribution timing, but medication is findable within 24-48 hours at alternative pharmacies.
If Your Pharmacy is Out:
- Call competing pharmacy chains (CVS, Walgreens, Rite Aid, Kroger, Walmart)
- Try independent pharmacies (often overlooked, may have stock)
- Order through mail-order pharmacy if your insurance plan allows it(Express Scripts, CVS Caremark, OptumRx)
Tirzepatide (Zepbound/Mounjaro): SHORTAGE RESOLVED
Timeline:
- April 2022: Mounjaro launches, immediate high demand
- November 2023: Zepbound approved, demand exceeds supply
- December 2024: FDA declares shortage resolved
- February 2026: Supply stable across all doses
What Changed:
Eli Lilly invested $9 billion in new manufacturing capacity at its Lebanon, Indiana site alone, with total manufacturing investments since 2020 exceeding $18 billion across U.S. and European facilities. Production tripled from 2023 to 2025.
Current Reality:
Widely available at most pharmacies. Eli Lilly prioritized pen supply for insured patients, vial supply through LillyDirect for cash-pay patients.
Unique Consideration:
Some insurance plans (notably CVS Caremark starting July 2025) excluded Zepbound from formulary despite availability. This is a coverage issue, not a shortage issue.
Liraglutide (Saxenda/Victoza): LIMITED SUPPLY
Timeline:
- August 2025: First generic liraglutide approved, Teva launches
- November 2025: Novo Nordisk reports Victoza shipping delays
- February 2026: Intermittent availability continues
What's Happening:
Novo Nordisk shifting production capacity to semaglutide (Wegovy/Ozempic) due to higher demand and profitability. Saxenda daily injection less popular than weekly semaglutide/tirzepatide. Company deprioritizing liraglutide manufacturing.
Alternatives:
- Generic liraglutide (if insurance covers)
- Switch to semaglutide or tirzepatide (requires prescription change)
- Use Wegovy or Zepbound instead (most patients prefer weekly vs daily)
Dulaglutide (Trulicity): SHORTAGE RESOLVED
Timeline:
- 2023-2024: Intermittent shortages
- June 2025: FDA declares shortage resolved
- February 2026: Stable supply
Current Reality:
Older GLP-1, less popular than semaglutide/tirzepatide. Rarely prescribed for new patients. Supply exceeds demand.
What Happened to Compounded GLP-1s?
The Rise of Compounding (2022-2025)
During shortages, FDA allowed compounding pharmacies to produce semaglutide and tirzepatide under 503A and 503B regulations. This provided access when brand-name drugs unavailable, at lower cost ($197-$397/month vs $1,000+).
Telehealth companies (Hims & Hers, Ro, Henry Meds) built business models around compounded GLP-1s. By late 2024, estimated 1-2 million patients using compounded versions.
The End of Compounding (2025)
FDA Grace Periods:
Semaglutide (Wegovy/Ozempic):
- Shortage declared resolved: February 2025
- 503A pharmacies: 60-day grace period ended April 2025
- 503B facilities: 90-day grace period ended May 2025
Tirzepatide (Zepbound/Mounjaro):
- Shortage declared resolved: December 2024
- 503A pharmacies: 60-day grace period ended February 2025
- 503B facilities: 90-day grace period ended March 2025
After Grace Periods: Compounding pharmacies can no longer produce semaglutide or tirzepatide for general dispensing. FDA can take enforcement action against facilities continuing production.
Exception: Individual patient-specific compounding still allowed if a pharmacist or physician prescriber documents medical necessity (e.g., patient needs different concentration, preservative-free formulation, etc.). This is rare and requires detailed justification.
Legal Challenges
Outsourcing Facilities Association (OFA) sued FDA twice:
- October 2024: Challenged tirzepatide shortage resolution
- February 2025: Challenged semaglutide shortage resolution
OFA claims FDA decision "reckless and arbitrary," arguing localized shortages still exist. Courts have not ruled in OFA's favor as of February 2026. Compounding exact replicas of GLP-1s remains illegal for routine use.
What Happened to Compounding Patients?
Transition Options:
- Switch to brand-name: Wegovy, Ozempic, Zepbound, Mounjaro
- Requires new prescription (different product)
- Insurance may cover if meets prior authorization criteria
- Cost: $50-$1,400/month depending on insurance
- Manufacturer programs: NovoCare, LillyDirect
- Cash-pay: $199-$549/month
- Immediate access
- Discontinue treatment: Some patients stopped
- Cost barriers (brand-name unaffordable)
- Weight regain within 3-6 months common
Where to Find GLP-1s When Your Pharmacy is Out
Pharmacy-by-Pharmacy Availability Strategies
Chain Pharmacies (Different Stock): Even within same chain, individual locations receive different inventory shipments. One CVS may be out while another 3 miles away has stock.
Call ahead script: "Hi, I have a prescription for [Wegovy/Zepbound] [dose]. Do you currently have it in stock? Can you tell me when your next shipment arrives?"
Best Pharmacies for Consistent Stock (Anecdotal Data):
- Costco: Bulk purchasing, reliable inventory
- Sam's Club: Similar to Costco
- Independent pharmacies: Lower volume, often overlooked by patients
- Grocery chain pharmacies: Kroger, Publix, HEB (regional)
- Big box stores: Walmart, Target
Avoid if Possible:
- Tourist-heavy areas (high transient prescription volume)
- Small urban pharmacies (limited storage)
- Pharmacies near obesity clinics (high GLP-1 prescription volume)
Mail-Order Pharmacy Options
Pros:
- 90-day supply (3-month buffer)
- Automatic refills
- Shipped directly to home
- Often better stock than retail
Cons:
- 7-14 day processing time
- Requires planning ahead
- Can't walk in for immediate need
- Some don't ship refrigerated medications
Major Mail-Order Pharmacies:
- Express Scripts
- CVS Caremark
- OptumRx
- Humana Pharmacy
- Kaiser Permanente Mail Order
How to Set Up:
- Contact insurance to confirm mail-order benefit
- Doctor sends 90-day prescription to mail-order pharmacy
- First fill ships, auto-refill 2 weeks before running out
- Confirm refrigerated shipping for injectables
Manufacturer Direct Programs
NovoCare Pharmacy (Wegovy/Ozempic):
- Direct from Novo Nordisk
- $199-$349/month cash pricing
- Ships refrigerated
- Enrollment: WegovyDirect.com
LillyDirect (Zepbound/Mounjaro):
- Direct from Eli Lilly
- Vial form only (self-injection)
- $399-$549/month
- Enrollment: LillyDirect.com
Disadvantage - some plans do not allow insurance use with coupons. Out of pocket pay only.
New Retail Options (2025-2026)
Costco Cash Program:
- Wegovy/Ozempic: $499/month cash price
- No insurance required
- Membership required ($60/year)
- Good for patients with high deductibles
Walmart Arrangements:
- Partnership with LillyDirect
- Zepbound available
- Pricing varies by location
GoodRx Partnerships:
- Wegovy injectable: $199 (months 1-2), $349 after
- Oral Wegovy pill: $149-$299
- Available at 70,000+ pharmacies nationwide
- Good for finding local availability
Alternative GLP-1 Options if First Choice Unavailable
GLP-1 Alternatives and Switching Strategies
Switching Between GLP-1s
Same Ingredient (e.g., Wegovy to Ozempic):
- No washout period needed
- Consult clinician for dose adjustments
- Doctor writes new prescription
- Insurance may have different coverage
Different Ingredients (e.g., Wegovy to Zepbound):
- Transition period is usually 1-2 weeks but your prescriber will determine if you need to wait before starting the new medication and for how long.
- Many doctors allow direct switch for supply reasons
- Retitrate over several weeks based on medication, dose, and patient response
Cost Consideration:
Sometimes switching from preferred insurance coverage (Wegovy copay $50) to non-covered alternative (Zepbound cash $549) doesn't make financial sense. Evaluate total cost before switching.
Preventing Future Supply Gaps
Refill Timing Strategy
Don't Wait Until Last Dose:
- Request refill when 7-10 days of supply remaining
- Allows time to find alternative pharmacy if stock-out
- Prevents missing doses while searching
90-Day Prescriptions:
- Ask doctor for 90-day supply
- Provides 3-month buffer
- Mail-order pharmacies require 90-day prescriptions
- Not all insurance plans allow 90-day fills
Backup Pharmacy:
- Identify 2-3 pharmacies that reliably stock your medication
- Transfer prescription between pharmacies allowed
- Keep backup pharmacy contact info saved
Dose Conservation (Emergency Only)
If Running Out and Can't Find Supply:
NOT Recommended Long-Term, But Temporary Options:
- Skip one dose: Semaglutide/tirzepatide half-life 5-7 days, missing one weekly dose maintains some therapeutic effect
- Split dose: If on 2.4mg Wegovy, could temporarily use 1.7mg while finding 2.4mg supply
- Extend interval: Instead of weekly, inject every 10 days (maintains partial effect)
Important: These are emergency measures only while actively searching for supply. Not sustainable long-term. Weight loss stalls. Side effects may increase when restarting full dose.
Insurance Considerations
Prior Authorization Expiration:
- Most PAs valid 6-12 months
- Mark calendar to renew 30 days before expiration
- Prevents coverage lapse mid-treatment
Formulary Changes:
- Insurance formularies update January 1 annually
- Check if your medication still covered
- Some plans dropped Zepbound, added Wegovy (or vice versa)
- Plan ahead for switches if needed
Note: Please note that compounded medications are not reviewed by the FDA for safety, quality, or efficacy. Any medication changes should be made under the guidance of a licensed healthcare provider.
The Bottom Line
The GLP-1 shortage that paralyzed access from 2022-2025 officially ended when FDA declared semaglutide (February 2025) and tirzepatide (December 2024) supplies stable. This resolved national shortages but didn't eliminate all supply challenges.
Current reality: Wegovy, Ozempic, Zepbound, and Mounjaro widely available at most pharmacies. Localized temporary stock-outs still occur, requiring patients to call multiple pharmacies or use mail-order alternatives.
Compounded GLP-1s ended: Grace periods expired May 2025, making compounded semaglutide/tirzepatide illegal except rare patient-specific cases. Approximately 1-2 million patients transitioned to brand-name medications or discontinued treatment.
New access options emerged: Oral Wegovy pill (January 2026) provides shortage-free alternative at $149-$299/month. Manufacturer direct programs (NovoCare, LillyDirect) guarantee supply. Retail cash programs (Costco $499, GoodRx $199-$349) expanded access.
Best strategies for consistent supply:
- Refill when 7-10 days remaining (don't wait until last dose)
- Identify 2-3 reliable backup pharmacies before needed
- Consider 90-day mail-order prescriptions for buffer
- Use manufacturer direct if insurance denials or stock-outs
- Oral Wegovy pill most reliable supply option currently
Liraglutide caution: Saxenda and Victoza experiencing limited supply as Novo Nordisk shifts production to semaglutide. Consider switching to Wegovy or Zepbound if on liraglutide and experiencing supply issues.
Future outlook: Unlikely to return to 2022-2024 shortage levels. Manufacturers invested tens of billions in production capacity — Eli Lilly alone committed over $18 billion across U.S. and European sites since 2020.
The shortage crisis is over, but vigilance remains necessary. Plan ahead, know your alternatives, and don't wait until the last minute to refill.
No waiting list. No insurance needed.
Frequently Asked Questions
Can I still get compounded semaglutide or tirzepatide?
No, routine compounding ended May 2025 when FDA grace periods expired. Compounding pharmacies cannot produce GLP-1s for general dispensing unless documenting specific patient medical necessity (extremely rare exceptions like preservative allergies). Patients must transition to brand-name Wegovy, Ozempic, Zepbound, or Mounjaro.
What if my pharmacy says they're on backorder?
Call competing pharmacy chains immediately, as stock varies by location even within same chain. Try independent pharmacies and warehouse clubs (Costco, Sam's Club) which often have better inventory. Mail-order pharmacies typically have more reliable stock for 90-day supplies. Manufacturer direct programs (NovoCare, LillyDirect) guarantee availability at $199-$549/month cash pricing.
Is the shortage really over or will it come back?
FDA declared shortages resolved based on manufacturer capacity meeting national demand, but localized temporary stock-outs still occur due to distribution logistics. Unlikely to return to 2022-2024 shortage levels unless demand increases 300%+ again. Manufacturers invested billions in production capacity to prevent future shortages. Monitor FDA drug shortage database for official status updates.
Can I switch from Wegovy to Zepbound if one is unavailable?
Yes, requires new prescription from doctor but no washout period needed for supply-driven switches (though 4-5 weeks medically recommended). Start at lowest Zepbound dose (2.5mg) and titrate up over 16-20 weeks even if on max Wegovy dose. Zepbound often shows slightly better weight loss (17% vs 15%) but different side effect profile. Insurance coverage may differ between the two medications.
What happens if I miss doses due to shortage?
Missing 1-2 weekly doses maintains some therapeutic effect due to long half-life (5-7 days), but missing 3+ weeks requires restarting at lower dose to prevent severe side effects. If you miss >5 days, FDA label recommends restarting titration schedule. Weight loss plateaus or reverses quickly when doses missed. Contact doctor immediately if supply disruption forces missed doses to discuss safe continuation plan.
Are oral GLP-1 pills easier to find than injections?
Yes, oral Wegovy pill launched January 2026 and never experienced shortage, making it most reliable option for consistent supply. Available at $149-$299/month through GoodRx and manufacturer programs. Also avoids injection supply chain issues (syringes, refrigeration). However, requires fasting 30 minutes before breakfast and daily dosing versus weekly injections. Insurance coverage varies, some plans cover oral while excluding injectable (or vice versa).